Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


ATP-specificity of succinyl-CoA synthetase from Blastocystis hominis.

Huang J, Nguyen VH, Hamblin KA, Maytum R, van der Giezen M, Fraser ME.

Acta Crystallogr D Struct Biol. 2019 Jul 1;75(Pt 7):647-659. doi: 10.1107/S2059798319007976. Epub 2019 Jun 26.


The Fluoroquinolone Finafloxacin Protects BALB/c Mice Against an Intranasal Infection With Francisella tularensis Strain SchuS4.

Barnes KB, Hamblin KA, Richards MI, Laws TR, Vente A, Atkins HS, Harding SV.

Front Microbiol. 2019 May 1;10:904. doi: 10.3389/fmicb.2019.00904. eCollection 2019.


Disulfiram, an alcohol dependence therapy, can inhibit the in vitro growth of Francisella tularensis.

Hamblin KA, Flick-Smith H, Barnes KB, Pereira-Leal JB, Surkont J, Hampson R, Atkins HS, Harding SV.

Int J Antimicrob Agents. 2019 Jul;54(1):85-88. doi: 10.1016/j.ijantimicag.2019.04.002. Epub 2019 Apr 25.


The Human Gut Colonizer Blastocystis Respires Using Complex II and Alternative Oxidase to Buffer Transient Oxygen Fluctuations in the Gut.

Tsaousis AD, Hamblin KA, Elliott CR, Young L, Rosell-Hidalgo A, Gourlay CW, Moore AL, van der Giezen M.

Front Cell Infect Microbiol. 2018 Oct 22;8:371. doi: 10.3389/fcimb.2018.00371. eCollection 2018.


Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei.

Barnes KB, Hamblin KA, Richards MI, Laws TR, Vente A, Atkins HS, Harding SV.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00082-17. doi: 10.1128/AAC.00082-17. Print 2017 Jul.


Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague.

Hamblin KA, Armstrong SJ, Barnes KB, Davies C, Laws T, Blanchard JD, Harding SV, Atkins HS.

Front Microbiol. 2017 Feb 6;8:91. doi: 10.3389/fmicb.2017.00091. eCollection 2017.


Engineering Nucleotide Specificity of Succinyl-CoA Synthetase in Blastocystis: The Emerging Role of Gatekeeper Residues.

Vashisht K, Verma S, Gupta S, Lynn AM, Dixit R, Mishra N, Valecha N, Hamblin KA, Maytum R, Pandey KC, van der Giezen M.

Biochemistry. 2017 Jan 24;56(3):534-542. doi: 10.1021/acs.biochem.6b00098. Epub 2017 Jan 11.


Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever.

Norville IH, Hatch GJ, Bewley KR, Atkinson DJ, Hamblin KA, Blanchard JD, Armstrong SJ, Pitman JK, Rayner E, Hall G, Vipond J, Atkins TP.

Antimicrob Agents Chemother. 2014 Sep;58(9):5510-8. doi: 10.1128/AAC.03443-14. Epub 2014 Jul 7.


The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy.

Hamblin KA, Wong JP, Blanchard JD, Atkins HS.

Front Cell Infect Microbiol. 2014 Jun 18;4:79. doi: 10.3389/fcimb.2014.00079. eCollection 2014. Review.


Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4.

Hamblin KA, Armstrong SJ, Barnes KB, Davies C, Wong JP, Blanchard JD, Harding SV, Simpson AJ, Atkins HS.

Antimicrob Agents Chemother. 2014 Jun;58(6):3053-9. doi: 10.1128/AAC.02555-13. Epub 2014 Mar 17.


Assessment of antimicrobial peptide LL-37 as a post-exposure therapy to protect against respiratory tularemia in mice.

Flick-Smith HC, Fox MA, Hamblin KA, Richards MI, Jenner DC, Laws TR, Phelps AL, Taylor C, Harding SV, Ulaeto DO, Atkins HS.

Peptides. 2013 May;43:96-101. doi: 10.1016/j.peptides.2013.02.024. Epub 2013 Mar 14.


Galleria mellonella as a model system to test the pharmacokinetics and efficacy of antibiotics against Burkholderia pseudomallei.

Thomas RJ, Hamblin KA, Armstrong SJ, Müller CM, Bokori-Brown M, Goldman S, Atkins HS, Titball RW.

Int J Antimicrob Agents. 2013 Apr;41(4):330-6. doi: 10.1016/j.ijantimicag.2012.12.009. Epub 2013 Feb 8.


Supplemental Content

Loading ...
Support Center